IPI201 / Isosceles Pharmaceuticals - LARVOL DELTA

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of IPI-201 Administered Intravenously in Healthy Male Participants (ANZCTR) - P1 | N=22 | Completed | Sponsor: Isosceles Pharmaceuticals Australia Pty Ltd | Recruiting ➔ Completed

Trial completion • Pain

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of IPI-201 Administered Intravenously in Healthy Male Participants (ANZCTR) - P1 | N=22 | Recruiting | Sponsor: Isosceles Pharmaceuticals Australia Pty Ltd | Initiation date: Apr 2026

Enrollment open • Trial initiation date • Pain

Effects of resorcinol isoprenyl benzene derivative IPI201 on natural killer cell cytotoxicity and tumor cell viability in human colorectal adenocarcinoma cells. (ASCO 2026) - "IPI201 induces tumor cell death independent of NK cells and enhances NK cell-associated cytotoxicity during pre- or -co-treatment. These effects may arise from increased NK cell survival and/or heightened tumor cell susceptibility to immune-mediated killing. To our knowledge, IPI201 is now the third known molecule alongside IL-2 and IL-15, that is independently sufficient to support NK cell survival."

Tumor cell • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor • IL15 • IL2

Evaluation of intravenous IPI201 in combination with anti–PD-1 therapy in a colorectal cancer mouse model. (ASCO 2026) - " MC38 colon tumors were implanted subcutaneously in mice and treated with vehicle, IPI201 (i.v.), anti-PD-1 (BE0156; i.p.), 5-fluorouracil (5-FU) (i.p.), or IPI201 plus anti-PD-1 at varying dose combinations once the implanted tumor reached a size of 75 mm3. IPI201 and PD-1 blockade combination improves survival, promotes tumor necrosis, and remodels the tumor microenvironment in a preclinical CRC model. These findings support further development of IPI201 as a combination immunotherapy strategy and provide a mechanistic rationale for evaluating resorcinyl isoprenyl benzene-based enhancers of checkpoint inhibition in CRC."

Combination therapy • IO biomarker • Preclinical • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • EGFR